Applied Medical Technology recalled 1,780 NutraGlide Nasal Feeding Tubes on August 12, 2025, after reports of distal tips detaching. This recall affects tubes distributed in Massachusetts and Rhode Island. The detachment poses a high risk for patients requiring enteral nutrition.
The nasal feeding tubes, NutraGlide, subject to this recall have distal tips that may detach at lower than expected forces.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Applied Medical Technology Inc or your healthcare provider for instructions. Notification method: Letter
Get instant alerts for Health & Personal Care recalls
Be the first to know. Free instant alerts to your inbox.
The recall includes NutraGlide Nasal Feeding Tubes with Stylet and ENFit, sizes 5 F - 6 F x 55, REF E NRT-05055-I. These tubes were distributed in the US, specifically in Massachusetts and Rhode Island.
The distal tips of the NutraGlide Nasal Feeding Tubes may detach at lower than expected forces. This defect poses a significant risk to patients who depend on these feeding tubes for nutrition, fluids, and medications.
There have been no reported injuries or incidents associated with this recall. The potential for detachment remains a serious concern for patient safety.
Patients and healthcare providers should stop using the NutraGlide Nasal Feeding Tubes immediately. Follow the recall instructions provided by Applied Medical Technology Inc. Contact the manufacturer or your healthcare provider for further instructions.
For more information, contact Applied Medical Technology Inc. at [insert phone number]. Additional details can be found on their website or through the FDA recall notice.
Get instant alerts for recalls that affect you. Free forever.
Taro Pharmaceuticals announced a market withdrawal of Diclofenac Sodium, Topical Gel, 3% on January 27, 2026. The withdrawal stems from out of specification viscosity results. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,057 bags of Acyclovir Sodium Injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers should cease use immediately and contact the manufacturer for guidance.
Fresenius Kabi Compounding recalled its vancomycin HCl injection on February 5, 2026, due to a lack of assurance of sterility. This Class II recall affects all lots distributed nationwide. Healthcare providers and consumers must stop using the product immediately.
Fresenius Kabi Compounding recalled 1,578 bags of vancomycin HCl injection on February 5, 2026. The company cited a lack of assurance of sterility as the reason for the recall. Healthcare providers and consumers should stop using the product immediately.
Fresenius Kabi Compounding recalled 1,410 bags of ketamine HCl injection on February 5, 2026. The recall stems from a lack of assurance of sterility, posing a high health risk. Healthcare providers and consumers must stop using this product immediately.
Fresenius Kabi Compounding recalled 10,548 bags of thiamine HCl injection on February 5, 2026. The recall follows a lack of assurance of sterility, posing a high health risk. Affected products include several lots expiring between February and May 2026.
Pro Numb Tattoo Numbing Spray was recalled due to cGMP deviations. The recall affects products distributed nationwide in the USA. Consumers should stop using the spray immediately and contact Pro Numb Tattoo Numbing Spray LLC for guidance.
Pro Numb Tattoo Numbing Spray was recalled on February 2, 2026 due to cGMP deviations. The product, containing 4% lidocaine, is distributed by Pro Numb Tattoo Numbing Spray LLC. Consumers should stop using it immediately and contact the company for further guidance.